Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) generates frequent news flow as a clinical-stage company developing natural and engineered bacteriophage therapies targeting specific pathogenic bacteria. Company press releases and Form 8-K filings describe how BiomX advances phage cocktails and personalized phage treatments for chronic conditions, including cystic fibrosis-related lung infections and diabetic foot disease. News coverage often centers on clinical trial progress, regulatory feedback, financing transactions and strategic updates that can influence the outlook for PHGE stock.
A major theme in BiomX news is the development of its phage product candidates. For BX004, a fixed multi-phage cocktail for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, the company has reported Phase 1b/2a data, FDA Fast Track and Orphan Drug designations, initiation of a Phase 2b trial, an FDA clinical hold related to a third-party nebulizer device, and ultimately the discontinuation of the Phase 2b study after internal review and Data Monitoring Committee feedback. Separate updates detail European enrollment, FDA correspondence on potential Phase 3 pathways, and safety reviews.
News items also highlight BiomX’s diabetic foot programs. The company has announced statistically significant positive topline Phase 2 results for BX211 in diabetic foot osteomyelitis and subsequent FDA feedback supporting the development pathway for BX011, a next-generation fixed multi-phage cocktail targeting Staphylococcus aureus in diabetic foot infections. Releases describe the rationale for prioritizing DFI, the incorporation of proprietary phages, and the role of non-dilutive funding from U.S. Defense Health Agency and Department of Navy-related sources.
Investors following PHGE can also expect updates on corporate and financial events, such as reverse stock split decisions, private placements of Series Y Convertible Preferred Stock and warrants, lease terminations at subsidiaries, and cost-cutting measures including workforce reductions. Together, these disclosures provide a detailed, evolving picture of BiomX’s clinical pipeline, regulatory interactions, capital structure and strategic alternatives. Bookmark this page to review new PHGE press releases, trial milestones and SEC-reported events as they are published.
Summary not available.
BiomX (PHGE) announced positive results from Part 1 of its Phase 1b/2a trial for BX004 targeting lung infections in cystic fibrosis (CF) patients. The treatment showed a significant bacterial load reduction of over 90% compared to placebo and no safety concerns. Enrollment for Part 2 is ongoing, with results expected in Q3 2023. Financially, BiomX reported a cash balance of $34.3 million as of Dec 31, 2022, down from $63.1 million the previous year. The company estimates its cash runway extends through mid-2024, supported by a $7.5 million private placement and a $5 million award from the Cystic Fibrosis Foundation.
BiomX Inc. (NYSE American: PHGE) has announced a conference call and live audio webcast on March 29, 2023, at 8:00 a.m. ET to discuss its fourth quarter and full year 2022 financial results along with business updates. The event will provide insights into the company's progress in developing natural and engineered phage therapies targeting pathogenic bacteria. Interested participants can join by dialing 1-877-407-0724 (U.S.) or 1-201-389-0898 (International), with the live and archived webcast available on BiomX's website.
BiomX (NYSE American: PHGE) announced a securities purchase agreement to issue and sell 30,608,163 shares at $0.245 per share, raising approximately $7.5 million through a private investment in public equity (PIPE) financing. The financing will close in two parts: $1.5 million expected soon, and the remainder pending stockholder approval in Q2 2023. Proceeds will fund clinical development of BX004 for lung infections in cystic fibrosis patients and other programs. The shares are unregistered under the Securities Act and may not be sold in the U.S. without proper registration.
BiomX has reported positive results from Part 1 of its Phase 1b/2a trial for BX004, a phage therapy targeting chronic pulmonary infections in cystic fibrosis patients caused by Pseudomonas aeruginosa. The therapy was found to be safe and well-tolerated across all patients, with preliminary efficacy signals noted, including a significant reduction in bacterial burden of 1.42 log10 CFU/g compared to placebo. Patient dosing for Part 2 has commenced, with results expected in Q3 2023. This trial marks a significant advancement as the first double-blind placebo-controlled study showcasing the effectiveness of a phage-based treatment for this condition.
BiomX Inc. (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022. The virtual presentation is scheduled for 10:30 AM EST.
BiomX is innovating in the microbiome sector with novel phage therapies targeting specific pathogenic bacteria. The presentation will be available via the Company’s website.
BiomX (PHGE) has made progress in enrolling patients for its Phase 1/2 trial of BX004, targeting lung infections in cystic fibrosis. Following challenges in patient recruitment due to COVID-19, enrollment is now expected to complete by year-end, with initial results anticipated in Q1 2023. The company reported a cash balance of $41.5 million, sufficient to support operations until at least mid-2024. Notably, it received a $5 million Therapeutics Development Award from the Cystic Fibrosis Foundation, bolstering its financial position.
BiomX Inc. (PHGE), a clinical-stage microbiome company, announced a conference call on November 9, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results and provide business updates. The conference will be accessible via phone or through a live audio webcast on the company's website. BiomX focuses on developing natural and engineered phage therapies aimed at treating chronic diseases by targeting specific pathogenic bacteria. More details can be found on their website.
BiomX Inc. (NYSE American: PHGE), a clinical-stage microbiome company, announced that CEO Jonathan Solomon will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 AM EST. The conference runs from September 12-14, 2022. Presentations will be available on-demand, and the webcasts can be accessed via the BiomX Investors section post-event. The company focuses on developing phage therapies targeting pathogenic bacteria to treat chronic diseases.
BiomX (PHGE) updates on its Phase 1b/2a trial for BX004, targeting lung infections in cystic fibrosis (CF), with results expected by Q3 2022. The company entered a collaboration with Boehringer Ingelheim to discover microbiome markers for inflammatory bowel disease. BiomX published significant research articles, including one in Cell, and has extended its cash runway through mid-2024 with a current cash position of $46.7 million. Despite a net loss of $7.5 million in Q2 2022, the company is focused on key milestones to enhance shareholder value.